Why have annualized relapse rates in RRMS trials decreased?
Take a look at our latest data visualization. It appears that there's been a substantial decrease in annualized relapse rates (ARRs) among patients in the placebo arm of RRMS trials over the last 2 decades. I'm interested in what may account for this change, and how those hypotheses may be tested. Please add your ideas below.